Novartis’ generic unit, Sandoz, Inc., has filed a complaint against Teva Pharmaceutical Industries in the U.S. District Court for the District of Columbia, for seeking approval of its generic Zocor products following an April 30, 2006 decision of the same Court. The decision in April granted Teva’s motion for summary judgment on the issue of whether its ANDA to market a generic version of Merck’s Zocor is entitled to 180-day Hatch-Waxman statutory exclusivity. The Court fo...